Pneumocystis pneumonia

Pneumocystis pneumonia
Field	Infectious disease, Pulmonology

Pneumocystis pneumonia. It is a form of fungal pneumonia caused by the opportunistic organism *Pneumocystis jirovecii*. The disease is a significant cause of illness and mortality in individuals with severely compromised immune systems, particularly those with advanced HIV infection, recipients of organ transplants, and patients undergoing intensive chemotherapy. While rare in the general population, its emergence was a defining feature of the early AIDS epidemic in the 1980s.

Signs and symptoms

The onset is often insidious, with non-specific symptoms that can progress over several weeks. Common clinical features include progressive dyspnea, a non-productive cough, fever, and fatigue. Physical examination may reveal tachypnea and tachycardia, but lung auscultation is frequently unremarkable despite significant hypoxemia. Severe cases can rapidly progress to acute respiratory distress syndrome and respiratory failure, necessitating intensive care support. The classic triad of dyspnea, cough, and fever in a susceptible host is highly suggestive.

Cause and pathophysiology

The causative agent is the fungus *Pneumocystis jirovecii*, which was historically misclassified as a protozoan. Transmission is believed to occur via the airborne route, with primary infection typically happening in early childhood, as evidenced by serological studies. In immunocompetent hosts, the organism exists as a latent, asymptomatic infection. Disease occurs upon reactivation or new exposure when cell-mediated immunity is profoundly impaired, specifically with deficits in CD4+ T cell function. The organism proliferates within the pulmonary alveoli, provoking an inflammatory response that leads to the characteristic foamy, eosinophilic exudate visible on histopathology, which impairs gas exchange.

Diagnosis

Definitive diagnosis requires microscopic identification of the organism in respiratory specimens. The gold standard is visualization of characteristic cysts or trophic forms on stains such as Grocott's methenamine silver stain or immunofluorescence assays performed on samples obtained via bronchoalveolar lavage or lung biopsy. Supporting laboratory findings often include an elevated serum lactate dehydrogenase level and marked arterial blood gas abnormalities revealing hypoxemia. Radiographically, chest X-ray typically shows bilateral, peri-hilar interstitial infiltrates, while high-resolution computed tomography is more sensitive, often revealing ground-glass opacities. Differential diagnosis includes other opportunistic infections like cytomegalovirus pneumonia and *Mycobacterium avium* complex infection.

Prevention

Primary prevention is centered on chemoprophylaxis for high-risk populations. The standard regimen, recommended by guidelines from the Centers for Disease Control and Prevention and the Infectious Diseases Society of America, is daily or weekly trimethoprim/sulfamethoxazole. For patients with sulfa allergies, alternatives include dapsone, atovaquone, or inhaled pentamidine. Prophylaxis is universally indicated for individuals with HIV whose CD4 count falls below 200 cells/µL and for recipients of solid organ transplants or hematopoietic stem cell transplantation during periods of intense immunosuppression. Environmental control measures are not standard due to the ubiquitous nature of the organism.

Treatment

First-line therapy for moderate to severe cases is high-dose trimethoprim/sulfamethoxazole, administered intravenously or orally. For patients with intolerance or contraindications, second-line agents include intravenous pentamidine, the combination of clindamycin and primaquine, or atovaquone. Adjunctive corticosteroid therapy, specifically prednisone, is strongly recommended for patients with moderate to severe hypoxemia, as it reduces inflammation and mortality, based on landmark studies from the National Institutes of Health. Treatment duration is typically 21 days, with careful monitoring for adverse drug reactions and clinical response.

Epidemiology

The disease is found worldwide and is almost exclusively an opportunistic infection. Its epidemiology shifted dramatically with the HIV/AIDS pandemic, where it became the most common AIDS-defining clinical condition in the United States and Europe before the advent of effective antiretroviral therapy. The introduction of widespread prophylaxis and highly active antiretroviral therapy has led to a significant decline in incidence among people with HIV. Today, the majority of cases occur in non-HIV immunocompromised hosts, including patients with hematological malignancies, those on long-term corticosteroid therapy, and recipients of solid organ transplants. It remains a persistent public health challenge in regions with limited access to HIV testing and modern immunosuppressive therapies.

Category:Fungal diseases Category:Pulmonology Category:Infectious diseases